Common Anti-Inflammatory Drug Added to COVID-19 Treatment Study
Excerpt from the Press Release:
United Kingdom (Precision Vaccinations)
A commonly used anti-inflammatory treatment has been added to the Randomised Evaluation of COVid-19 thERapY (RECOVERY) study, the world’s largest clinical trial of treatments for patients hospitalized with COVID-19.
Professor Peter Horby at the University of Oxford and co-Chief Investigator of the RECOVERY trial, said in a press release on November 26, 2020, ‘Colchicine is an attractive drug to evaluate as it is very well understood, inexpensive and widely available. If it works it would be another COVID-19 treatment that could be used immediately worldwide, even in the poorest countries.’
Click the button below to continue reading the Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?